Header

UZH-Logo

Maintenance Infos

Mechanisms and biomarkers of successful allergen-specific immunotherapy


López, Juan-Felipe; imam, Manal Bel; Satitsuksanoa, Pattraporn; Lems, Sophieke; Yang, Minglin; Hwang, Yu-Kyoung; Losol, Purevsuren; Choi, Jun-Pyo; Kim, Sae-Hoon; Chang, Yoon-Seok; Akdis, Mübeccel; Akdis, Cezmi A; van de Veen, Willem (2022). Mechanisms and biomarkers of successful allergen-specific immunotherapy. Asia Pacific Allergy, 12(4):e45.

Abstract

Allergen-specific immunotherapy (AIT) is considered the only curative treatment for allergic diseases mediated by immunoglobulin E (IgE). Currently, the route of administration depends both on the different types of causal allergens and on its effectiveness and safety profile. Several studies have reported the mechanisms and changes in humoral and cellular response underlying AIT; however, the full picture remains unknown. Knowledge of who can benefit from this type of treatment is urgently needed due to the patient safety risks and costs of AIT. In vivo or in vitro biomarkers have become a strategy to predict clinical outcomes in precision medicine. There are currently no standardized biomarkers that allow determining successful responses to AIT, however, some studies have found differences between responders and nonresponders. In addition, different candidates have been postulated that may have the potential to become biomarkers. In this review, we aim to summarize the findings to date related to biomarkers in different IgE-mediated allergic diseases (respiratory, food, and venom allergy) with the potential to define who will benefit from AIT.

Abstract

Allergen-specific immunotherapy (AIT) is considered the only curative treatment for allergic diseases mediated by immunoglobulin E (IgE). Currently, the route of administration depends both on the different types of causal allergens and on its effectiveness and safety profile. Several studies have reported the mechanisms and changes in humoral and cellular response underlying AIT; however, the full picture remains unknown. Knowledge of who can benefit from this type of treatment is urgently needed due to the patient safety risks and costs of AIT. In vivo or in vitro biomarkers have become a strategy to predict clinical outcomes in precision medicine. There are currently no standardized biomarkers that allow determining successful responses to AIT, however, some studies have found differences between responders and nonresponders. In addition, different candidates have been postulated that may have the potential to become biomarkers. In this review, we aim to summarize the findings to date related to biomarkers in different IgE-mediated allergic diseases (respiratory, food, and venom allergy) with the potential to define who will benefit from AIT.

Statistics

Citations

Dimensions.ai Metrics
6 citations in Web of Science®
8 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

38 downloads since deposited on 09 Dec 2022
24 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Swiss Institute of Allergy and Asthma Research
Dewey Decimal Classification:610 Medicine & health
Uncontrolled Keywords:Dermatology, Immunology and Allergy
Language:English
Date:17 October 2022
Deposited On:09 Dec 2022 16:50
Last Modified:27 Feb 2024 02:52
Publisher:Asia Pacific Association of Allergy, Asthma and Clinical Immunology
ISSN:2233-8268
OA Status:Gold
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.5415/apallergy.2022.12.e45
PubMed ID:36452016
  • Content: Published Version
  • Licence: Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)